Impact of subclinical hypothyroidism on the insulin resistance and lipid profiles of PCOS patients
YIN Dongmei1 RUAN Xiangyan1▲ TIAN Xuanxuan1 LU Yongjun2
1.Department of Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China;
2.Department of Obstetrics and Gynecology, Tongzhou Maternal and Child Health Hospital of Beijing, Beijing 101101, China
Abstract：Objective To evaluate the characteristics of insulin resistance and lipid metabolism of PCOS patients with SCH. Methods A total of 200 patients with PCOS were recruited at the Department of Endocrinology, Beijing Obstetrics and Gynecology Hospital from September 2015 to October 2016. And they were divided into two groups: 41 cases of subclinical hypothyroidism (SCH-PCOS group) as study group and 159 cases of normal thyroid function (EU-PCOS group) as control group. The clinical features, sex hormone levels, fasting insulin levels and serum lipids between the groups were investigated. Results Body mass index (BMI), fasting insulin (FIN) and homeostatic model assessment -insulin resistance (HOMA-IR ) were higher than those in SCH-PCOS group (P ＜ 0.05). Lipid metabolism was slightly abnormal, but the difference was not statistically significant (P > 0.05). Conclusion The analysis indicates that PCOS complicated with SCH patients have more severe obesity and insulin resistance than those with normal thyroid functions.
[1] Delitala AP，Capobianco G，Delitala G，et al. Polycystic ovary syndrome，adipose tissue and metabolic syndrome [J]. Arch Gynecol Obstet，2017，296（3）：405-419.
[2] Singla R，Gupta Y，Khemani M，et al. Thyroid disorders and polycystic ovary syndrome：an emerging relationship [J]. Indian J Endocrinol Metab，2015，19（1）：25-29.
[3] Tagliaferri V，Romualdi D，Guido M，et al. The link between metabolic features and TSH levels in polycystic ovary syndrome is modulated by the body weight：an euglycaemic-hyperinsulinaemic clamp study [J]. Eur J Endocrinol，2016， 175（5）：433-441.
[4] Trakakis E，Pergialiotis V，Hatziagelaki E，et al. Subclinical hypothyroidism does not influence the metabolic and hormonal profile of women with PCOS [J]. Horm Mol Biol Clin Investig，2017，31（3）.
[5] Lu YH，Xia ZL，Ma YY，et al. Subclinical hypothyroidism is associated with metabolic syndrome and clomiphene citrate resistance in women with polycystic ovary syndrome [J]. Gynecol Endocrinol，2016，32（10）：852-855.
[6] Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome（PCOS）[J]. Hum Reprod，2004，19（1）：41-47.
[7] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组.甲状腺疾病诊治指南—甲状腺功能减退症[J].中华内科杂志，2007，46（11）：967-971.
[8] Anagnostis P，Tarlatzis BC，Kauffman RP. Polycystic ovarian syndrome （PCOS）：long-term metabolic consequences [J]. Metabolism，2017，10（17）：30 274.
[9] Xu H，Han Y，Lou J，et al. PDGFRA，HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer [J]. Oncotarget，2017，13，8（41）：69 520-69 526.
[10] Kiranmayee D，Kavya K，Himabindu Y，et al. Correlations between anthropometry and lipid profile in women with PCOS [J]. J Hum Reprod Sci，2017，10（3）：167-172.
[11] Petta S，Ciresi A，Bianco J，et al. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS [J]. PLoS One，2017，12（11）：e0 186 136.
[12] Delitala AP，Fanciulli G，Pes GM，et al. Thyroid hormones，metabolic syndrome and its components [J]. Endocr Metab Immune Disord Drug Targets，2017，17（1）：56-62.
[13] de-Medeiros SF，Yamamoto MMW，de-Medeiros MAS，et al. Should subclinical hypothyroidism be an exclusion criterion for the diagnosis of polycystic ovary syndrome？[J]. J Reprod Infertil，2017，18（2）：242-250.
[14] Gutch M，Rungta S，Kumar S，et al. Thyroid functions and serum lipid profile in metabolic syndrome [J]. Biomed J，2017，40（3）：147-153.
[15] Enzevaei A，Salehpour S，Tohidi M，et al. Subclinical hypothyroidism and insulin resistance in polycystic ovary syndro me：is there a relationship？[J]. Iran J Reprod Med，2014，12（7）：481-486.
[16] 岳芳芝，张冬梅，龚斐，等.多囊卵巢综合征患者亚临床甲状腺功能减退与其内分泌代谢特征的关系[J].中南大学学报：医学版，2017，42（8）：940-946.
[17] Lu YH，Xia ZL，Ma YY，et al. Subclinical hypothyroidism is associated with metabolic syndrome and clomiphene citrate resistance in women with polycystic ovary syndrome [J]. Gynecol Endocrinol，2016，32（10）：852-855.
[18] Pergialiotis V，Konstantopoulos P，Prodromidou A，et al. Management of endocrine disease： the impact of subclinical hypothyroidism on anthropometric characteristics，lipid，glucose and hormonal profile of PCOS patients：a systematic review and meta-analysis [J]. Eur J Endocrinol，2017，176（3）：R159-R166.
[19] Morgante G，Musacchio MC，Orvieto R，et al. Alterations in thyroid function among the different polycystic ovary syndrome phenotypes [J]. Gynecol Endocrinol，2013，29（11）：967-969.
[20] Trummer C，Schwetz V，Giuliani A，et al. Impact of elevated thyroid-stimulating hormone levels in polycystic ovary syndrome [J]. Gynecol Endocrinol，2015，31（10）：819-823.
[21] Li X，Wang Y，Guan Q，et al. The lipid-lowering effect of levothyroxine in patients with subclinical hypothyroidism：a systematic review and meta-analysis of randomized controlled trials [J]. Clin Endocrinol （Oxf），2017， 87（1）：1-9.
[22] Hassan A，Altamirano-Ufion A，Zulfiqar B，et al. Sub-clinical hypothyroidism and its association with increased cardiovascular mortality：call for action [J]. Cardiol Res Pract，2017，8（2）：31-35.
2018, Vol. 15 
京公网安备 11010502046598号